A young and savvy, yet experienced and accomplished investments mogul since ´01; Michael has amassed a fortune as a private self investor. Recently starting his own successful blog and turning it in to a corporation — MiV Investments Inc., a company offering advice to thousands of people worldwide and attracting contracts from various reputable sources. The financial news portal can be found at www.StocksHaven.com. Michael has reached Expert Stock Analyst status from a variety of accredited publications.
Articles by Michael Vlaicu
CardioCor Helping Americans Lose Weight Faster (PINK:CDOI.PK)
Pending IND Targetting a 28B AMD Market (OTC:ACTC.OB)
W2 Energy Redefines the Renewable Alternative Energy Industry (PINK:WTWO.PK)
A New Star Emerges in Diverse Media Group (PINK:DVME.PK)
XTend Medical Looks Towards Breakthrough Cancer Detection Nanotechology (PINK:XMDC.PK)
BizAuctions Looks to Rebound During Holiday Season (OTC:BZCN.OB)
News Awaits for AVAX's Phase II and Phase III Clinical Trials (OTC:AVXT.PK)
Paradigm Medical Rebounds as Investors Await Four New Devices (OTC:PDMI.PK)
Guided Therapeutics Targets One Billion Dollar Market (OTC:GTHP.OB)
Soligenix Aims for Bright Future Ahead (OTC:SNGX.OB)
FDA Play: Massive Potential, Undervalued, Gaining Momentum (OTC:SNGX.OB)
American Scientific Resources (PINK:ASFX.PK) Looks to Rise Up
NeoPharm Inc. (OTC:NEOL) Looks For Bright News in 4Q09
NDA Filing Nears for Biovest (OTC:BVTI)
LifeLine BioTechnologies Looks Ahead of FDA Decision (OTC:LLBO)
Provectus Takes Aim to Treat Five Types of Cancer (OTC:PVCT)
StocksHaven Investments profiles Nutra Pharma Inc.(OTC:NPHC)
StocksHaven Investments Profiles Imaging3's (OTC:IMGG) FDA Seeking Medical Device
StocksHaven Investments profiles GenVec and it's lead product TNFerade (NASDAQ:GNVC)
StocksHaven Investments Takes a Closer Look at Muscle Flex Inc. (OTC:MFLI)
Adeona Prepares Three Drugs for NDA Submission (AMEX:AEN)
Derma Sciences (OTC:DSCI) targets a prescription drug market that is 5x its present market cap
StocksHaven Investments takes a closer look at INVO BioScience Inc.
StocksHaven Investments profiles Biomoda Inc. (OTC:BMOD)
StocksHaven Investments Engagee in a Conversation with SymPowerco Corp CEO, John Davenport (PINK:SYMW)
StocksHaven Investments takes a closer look at the past performances in (OTC:SPNG), (NASDAQ:MESA), (AMEX:HEB), (OTC:ACCP), (OTC:NEPH), (OTC:BIEL), (NASDAQ:TESTR), (PINK:HTDS),(NASDAQ:SOMX),(PINK:SYMW)
StocksHaven Investments news portal takes a closer look at Javelin Pharmaceuticals (AMEX:JAV), which hopes its three drugs in Phase III, one of which already has European approval will make a splash within the pain medication market.
StocksHaven Investments news portal takes a closer look at SymPowerco Corp. (PINK:SYMW), which hopes its majority-owned subsidiary, Polygenic Power Systems alongside the recent government grant will propel it into future success.
StocksHaven Investments news portal takes a closer look at Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX), which hopes its drug, Silenor will be approved for the treatment of insomnia.
StocksHaven Investments takes a look at Hard to Treat Diseases, Inc. (PINK:HTDS) which may profit from the upcoming flu season
The following article was written and contributed by a highly regarded investor and member within the StocksHaven Investments community, Jeff Lawson:
With the recent passage and signing of the Credit Card Accountability, Responsibility, and Disclosure Act of 2009 (the Credit CARD Act), some chang...
Shares of the neuroscience-based biotechnology company look to be at a favourable price point (NYSE:ELN)
Aradigm Corporation
(Public, OTC:ARDM)
Aradigm is a company with a lot of positive long-term gains, especially with regards to its product pipeline involving the inhaled Cipro product (ILCH) for BE and CF, however the short-term play is a very different story. This company lacks visibility and the ability to fully utilize press release syndication to maximize potential reach for investors, and also engages in massive dilution in order to maintain ongoing operations. Moreover, the financial position also suffers as the company is enduring a heavy amount of cash burn every year with zero revenues as of Q1 (Mar´09). There is also a big question mark when it comes to partnerships — who will step up to the plate and infuse the cash which is so badly sought after?
The Launching of TerreStar-1 Looks to Propel TerreStar Corp. (NASDAQ: TSTR) for Financial Success
StocksHaven Investments news portal takes a closer look at Access Pharmaceuticals (OTC:ACCP), which hopes its drug, MuGard will be a big hit in Europe.
StocksHaven Investments news portal takes a closer look at BioElectronics Corporation (OTC:BIEL), which hopes its drug, Allay (TM) - Menstrual Pain Therapy will turn the business' fortunes around and make way for a positive future ahead.
Nephros prepares for a year thats bound to feel like a roller coaster ride.
Novel Osteoarthritis Treatment by Nuvo (TSE:NRI) confident of FDA approval.
BioDelivery (NASDAQ:BDSI) Investors Confident Pre-FDA Announcement
StocksHaven Investments news portal takes a closer look at Access Pharmaceuticals (OTC:ACCP), which looks ahead for a very successful year with MuGard and their multi-national product distribution deals and partnerships.
Note: StocksHaven Investments is up 121% from the initial buy on May/8/09 of(AMEX:HEB)
StocksHaven Investments' reader analyzes and deciphers the latest information on Hemispherx (AMEX:HEB) Ampligen
StocksHaven Investments news portal takes a closer look at Hemispherx Biopharma (AMEX:HEB), and its drug Ampligen which is used as an adjuvant to combat H5N1 (Swine Flu)
StocksHaven Investments news portal takes a closer look at Hemispherx Biopharma (AMEX:HEB), and analyzes the potential PPS should Ampligen see FDA approval in the coming weeks.
StocksHaven Investments news portal takes a closer look at the Consumer Confidence Index as of May 2009, which displays high optimism towards a faster than expected economic recovery.